Synapse - Eytan Stein

Results (30)

A phase 1 study of LY3410738, a first-in-class covalent inhibitor of mutant IDH in advanced myeloid malignancies (trial in progress)

Meeting Abstract

Stein, E. M.; Konopleva, M.; Gilmour, R.; Szpurka, A. M.; Hill, E.; Ward, R.; Kantarjian, H. M.; Dinardo, C. D.
Blood (2020)

Fulltext@MSK | Save

Initial results from a biomarker-directed phase 2 trial of SY-1425, a potent and selective RAR alpha agonist, in combination with azacitidine in relapsed/refractory acute myeloid leukemia

Meeting Abstract

Stein, E. M.; De Botton, S.; Cluzeau, T.; Pigneux, A.; Liesveld, J. L.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Braun, T.; Bixby, D. L.; more...
Blood (2020)

Fulltext@MSK | Save

Enasidenib (ENA) monotherapy with addition of azacitidine in non-responders is effective in older patients with newly diagnosed IDH2 mutated acute myeloid leukemia (AML): A completed phase 2/1b sub-study of the beat AML master trial

Meeting Abstract

Stein, E. M.; Huang, Y.; Borate, U.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Schiller, G. J.; Olin, R. L.; Foran, J. M.; more...
Blood (2020)

Fulltext@MSK | Save

Venetoclax therapy for relapsed and treatment refractory AML: Clinical outcomes and molecular predictors

Meeting Abstract

Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J. L.; King, A. C.; Daniyan, A.; Famulare, C.; Cuello, B. M.; more...
Blood (2020)

Fulltext@MSK | Save

Clinical outcomes of acute myeloid leukemia patients bridged to allogeneic stem cell transplant by venetoclax combination therapy

Meeting Abstract

Stahl, M.; Menghrajani, K.; Derkach, A.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; Barker, J.; more...
Blood (2020)

Fulltext@MSK | Save

Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia

Meeting Abstract

Stahl, M.; Derkach, A.; Famulare, C.; Cho, C.; Devlin, S.; Farnoud, N.; Menghrajani, K.; Patel, M. A.; Cai, S. F.; Geyer, M. B.; more...
Blood (2020)

Fulltext@MSK | Save

Impact of additional cytogenetic abnormalities and complex karyotype on event-free survival in acute promyelocytic leukemia: Analysis from a single academic center plus the APML4 study

Meeting Abstract

Epstein-Peterson, Z. D.; Rajeeve, S.; Derkach, A.; Park, J. H.; Stein, E. M.; Zhang, Y.; Iland, H. J.; Tallman, M. S.
Blood (2020)

Fulltext@MSK | Save

Molecular characterization of clinical response and relapse in patients with IDH1-mutant newly diagnosed acute myeloid leukemia treated with ivosidenib and azacitidine

Meeting Abstract

Daigle, S. R.; Choe, S.; DiNardo, C. D.; Stein, A. S.; Stein, E. M.; Fathi, A. T.; Frankfurt, O.; Schuh, A. C.; Döhner, H.; Martinelli, G.; more...
Blood (2020)

Fulltext@MSK | Save

SY-1425, a potent and selective RARα agonist, in combination with azacitidine demonstrates a high complete response rate and a rapid onset of response in RARA-positive newly diagnosed unfit acute myeloid leukemia